Everolimus (Afinitor, Torpenz, Zortress) — 2026 Medicare Part D coverage
everolimus — sold as Afinitor, Torpenz, Zortress: 26 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover everolimus?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| everolimus 0.25 MG Oral Tablet generic · RxCUI 977427 | 328 (100%) | 4 | 328 | 0 | 48 |
| everolimus 0.5 MG Oral Tablet generic · RxCUI 977434 | 328 (100%) | 5 | 328 | 0 | 48 |
| everolimus 0.75 MG Oral Tablet generic · RxCUI 977438 | 328 (100%) | 5 | 328 | 0 | 48 |
| everolimus 1 MG Oral Tablet generic · RxCUI 2056895 | 328 (100%) | 5 | 328 | 0 | 49 |
| everolimus 10 MG Oral Tablet generic · RxCUI 845507 | 328 (100%) | 5 | 325 | 0 | 296 |
| everolimus 2 MG Tablet for Oral Suspension generic · RxCUI 1308428 | 328 (100%) | 5 | 325 | 0 | 250 |
| everolimus 2.5 MG Oral Tablet generic · RxCUI 998189 | 328 (100%) | 5 | 325 | 0 | 296 |
| everolimus 3 MG Tablet for Oral Suspension generic · RxCUI 1308430 | 328 (100%) | 5 | 325 | 0 | 250 |
| everolimus 5 MG Oral Tablet generic · RxCUI 845515 | 328 (100%) | 5 | 325 | 0 | 296 |
| everolimus 5 MG Tablet for Oral Suspension generic · RxCUI 1308432 | 328 (100%) | 5 | 325 | 0 | 253 |
| everolimus 7.5 MG Oral Tablet generic · RxCUI 1119400 | 328 (100%) | 5 | 325 | 0 | 296 |
| TORPENZ 10 MG Oral Tablet brand · RxCUI 2685204 | 236 (72%) | 5 | 234 | 0 | 220 |
| TORPENZ 2.5 MG Oral Tablet brand · RxCUI 2685202 | 236 (72%) | 5 | 234 | 0 | 220 |
| TORPENZ 5 MG Oral Tablet brand · RxCUI 2685206 | 236 (72%) | 5 | 234 | 0 | 220 |
| TORPENZ 7.5 MG Oral Tablet brand · RxCUI 2685208 | 236 (72%) | 5 | 234 | 0 | 220 |
| AFINITOR 2.5 MG Oral Tablet brand · RxCUI 998191 | 2 (1%) | 1 | 2 | 0 | 2 |
| AFINITOR 5 MG Oral Tablet brand · RxCUI 845518 | 2 (1%) | 1 | 2 | 0 | 2 |
| AFINITOR 7.5 MG Oral Tablet brand · RxCUI 1119402 | 2 (1%) | 1 | 2 | 0 | 2 |
| ZORTRESS 1 MG Oral Tablet brand · RxCUI 2056897 | 2 (1%) | 1 | 2 | 0 | 0 |
| Zortress 0.25 MG Oral Tablet brand · RxCUI 977431 | 2 (1%) | 1 | 2 | 0 | 0 |
| Zortress 0.5 MG Oral Tablet brand · RxCUI 977436 | 2 (1%) | 1 | 2 | 0 | 0 |
| Zortress 0.75 MG Oral Tablet brand · RxCUI 977440 | 2 (1%) | 1 | 2 | 0 | 0 |
| AFINITOR 10 MG Oral Tablet brand · RxCUI 845512 | 1 (0%) | 1 | 1 | 0 | 1 |
| AFINITOR DISPERZ 2 MG Tablet for Oral Suspension brand · RxCUI 1310138 | 1 (0%) | 1 | 1 | 0 | 1 |
| AFINITOR DISPERZ 3 MG Tablet for Oral Suspension brand · RxCUI 1310144 | 1 (0%) | 1 | 1 | 0 | 1 |
| AFINITOR DISPERZ 5 MG Tablet for Oral Suspension brand · RxCUI 1310147 | 1 (0%) | 1 | 1 | 0 | 1 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.